Drug Type Small molecule drug |
Synonyms SYHA 1813, SYHA1813 |
Target |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | - | - | |
Gliosarcoma | Phase 1 | CN | 20 Dec 2023 | |
Brain metastases | Phase 1 | CN | 26 May 2021 | |
Colorectal Cancer | Phase 1 | CN | 26 May 2021 | |
Giant Cell Tumor of Tendon Sheath | Phase 1 | CN | 26 May 2021 | |
High grade glioma | Phase 1 | CN | 26 May 2021 | |
Kidney Neoplasms | Phase 1 | CN | 26 May 2021 | |
Lung Cancer | Phase 1 | CN | 26 May 2021 | |
Stomach Cancer | Phase 1 | CN | 26 May 2021 | |
Thyroid Cancer | Phase 1 | CN | 26 May 2021 |
Phase 1 | 11 | SYHA1813 15mg or 20mg | stpexaqtyg(ygvzraxnrj) = pksguzvnap zohbsbpbyb (ojnpnxoayn, 16.8-76.6) View more | Positive | 21 Oct 2023 | ||
Phase 1 | 14 | yerxjqjrfp(cbhpqfbgza) = mdrxpmazwa uyzmmvrbyh (raxjeztahg ) View more | - | 08 Mar 2023 | |||
Phase 1 | 14 | yttvjhdjig(bfezvbquoo) = The dose-limiting toxicities (DLTs) were grade (G) 4 hypertension (n = 1) and G3 mucositis oral (n =1) at 30 mg. gbhzzvghnw (zmdczcuykp ) View more | Positive | 10 Sep 2022 |